Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
List view / Grid view
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
A study has shown that two products of bacterial bile metabolism boost the conversion of precursor T cells into peripheral Tregs, which suppress chronic inflammation in the colon.
Researchers have discovered that an antibody which targets the CD36 protein prevents Tregs from protecting tumours against immunotherapies in mouse models.
Researchers have discovered that MYC cancers use the cell’s machinery to make lipids and identified a lipid signature, which could be exploited in the development of new therapies.
Researchers have found two biomarkers which play a significant role in the invasion of tumours by T-cells.